The P2X7 receptor in mucosal adaptive immunity.

Authors:
Grassi F; Marino R.

Journal:
Purinergic Signal

Publication Year: 2023

DOI:
10.1007/s11302-023-09939-w

PMCID:
PMC10828151

PMID:
37067746

View on PubMed View on PMC View Publisher
Journal Information

Full Title: Purinergic Signal

Abbreviation: Purinergic Signal

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Biochemistry

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
P2Y<sub>11</sub>/IL-1 receptor crosstalk controls macrophage inflammation: a novel target for anti-…
Klaver D; Thurnher M. (2023) - Transparency Score: 3/6
Targeting the A3 adenosine receptor to treat hepatocellular carcinoma: anti-cancer and hepatoprotec…
Fishman P; Stemmer SM; Bareket-Samish A and 2 more (2023) - Transparency Score: 3/6
Burnstock oration - purinergic signalling in kidney transplantation.
Dwyer KM. (2022) - Transparency Score: 3/6
Characterisation of P2Y receptor subtypes mediating vasodilation and vasoconstriction of rat pulmon…
Dales MO; Mitchell C; Gurney AM and 2 more (2022) - Transparency Score: 3/6
Ectonucleotidases as bridge between the ATP and adenosine world: reflections on Geoffrey Burnstock.
Schrader J. (2022) - Transparency Score: 3/6
View All Papers from This Journal
Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Declarations Competing interestsFG is the Founder of MV BioTherapeutics, a biotech company developing biotherapeutics targeting extracellular ATP Ethical approvalNot applicable. Conflicts of interestFG is the Founder of MV BioTherapeutics, a biotech company developing biotherapeutics targeting extracellular ATP Competing interests FG is the Founder of MV BioTherapeutics, a biotech company developing biotherapeutics targeting extracellular ATP Conflicts of interest FG is the Founder of MV BioTherapeutics, a biotech company developing biotherapeutics targeting extracellular ATP "

Evidence found in paper:

"Funding Open access funding provided by Università della Svizzera italiana Swiss National Science Foundation, grant no. SNSF 310030_192531. R.M. is funded by Swiss-European Mobility Program."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025